Thiomuscimol
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Thiomuscimol, also known as 5-aminomethyl-3-isothiazol, is a synthetic GABAA receptor agonist which is structurally related to the naturally occurring GABAA receptor agonist muscimol (found in Amanita muscaria).[2][3] It is approximately equipotent with muscimol as a GABAA receptor agonist in vitro.[4] Unlike muscimol however, thiomuscimol does not to any extent additionally act as a GABA reuptake inhibitor.[2] On the other hand, like muscimol, it is a substrate for and metabolized by GABA transaminase (GABA-T), which is said to have limited its usefulness and application in animal behavioral studies.[2][5] The drug was first described in the scientific literature by Povl Krogsgaard-Larsen and colleagues by 1976.[1][6][3] It was encountered as a novel designer drug online in 2024.[7][8]
- None
| |
| Clinical data | |
|---|---|
| Other names | 5-Aminomethyl-3-isothiazol |
| Drug class | GABAA receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C4H6N2OS |
| Molar mass | 130.17 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 140 °C (284 °F) (decomp.)[1] |
| |
| |
